文献速递新发突发、热带与寄生虫病

青蒿甲醚-苯芴醇联合阿莫地喹与单用青蒿甲醚-苯芴醇治疗青蒿素耐药无并发症恶性疟:开放标签随机多中心试验

Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial.
PubMed 文献 · Lancet Infect Dis · 2022-03-08

在柬埔寨西部、东部和越南五家医院或卫生中心开展开放标签随机试验,310例2-65岁无并发症恶性疟患者随机接受青蒿甲醚-苯芴醇单药或联合阿莫地喹治疗。42天PCR校正有效率联合组97% vs 单药组95%,复发HR 0.6(95%CI 0.2-1.9,p=0.38);联合组轻度胃肠道不良事件和心动过缓更多。

要点

  • 联合组42天PCR校正有效率97%(151/156)vs 单药组95%(146/154),复发HR 0.6(95%CI 0.2-1.9,p=0.38)。
  • pfkelch13突变感染者中联合组有效率96%(89/93)vs 单药组90%(73/81),HR 0.44(95%CI 0.14-1.40,p=0.17)。
  • 联合组呕吐8% vs 2%(p=0.03)、恶心7% vs 2%(p=0.05)、心动过缓61% vs 38%(p=0.0001)均高于单药组。

核心结论

  • 作者认为青蒿甲醚-苯芴醇联合阿莫地喹可作为大湄公河次区域耐多药恶性疟一线治疗的替代方案,并可能延长青蒿甲醚-苯芴醇在疟疾流行人群中的治疗寿命。

研究设计与样本

  • 在柬埔寨西部、柬埔寨东部和越南三地五家医院或卫生中心开展开放标签随机多中心试验,2018年3月18日至2020年1月30日共310例2-65岁无并发症恶性疟患者随机分组(1:1,区组8-12例)。
  • 154例接受青蒿甲醚-苯芴醇单药(按WHO指南给药),156例接受青蒿甲醚-苯芴醇联合阿莫地喹(10 mg碱基/kg/天),均口服3天内6剂;所有患者在开始研究治疗24小时后单剂伯氨喹(0·25 mg/kg)。
  • 主要结局为意向性分析下针对原虫复燃的42天Kaplan-Meier PCR校正有效率,安全性为次要结局;试验注册号NCT03355664。

主要发现

  • 42天PCR校正有效率联合组97%(95%CI 92-99,151/156)vs 单药组95%(95%CI 89-97,146/154),复燃HR 0.6(95%CI 0.2-1.9,p=0.38)。
  • 13例复燃中12例发生于305例感染中的174例(57%)pfkelch13突变(提示青蒿素耐药)感染者;该亚组42天有效率联合组96%(89/93)vs 单药组90%(73/81),复燃HR 0.44(95%CI 0.14-1.40,p=0.17)。
  • 轻度(1-2级)不良事件主要为胃肠道反应,联合组多于单药组:呕吐12例(8%)vs 3例(2%),p=0.03;恶心11例(7%)vs 3例(2%),p=0.05。
  • 治疗1小时内需重新给药的早期呕吐:单药组0/154 vs 联合组5例(3%),p=0.06;任何级别心动过缓(≤54次/分)单药组59/154(38%)vs 联合组95/156(61%),p=0.0001。

关键数值与推荐

  • 青蒿甲醚-苯芴醇单药按WHO指南给药;联合组阿莫地喹剂量为10 mg碱基/kg/天;两组均口服3天内6剂。
  • 所有患者于开始研究治疗24小时后接受单剂伯氨喹0·25 mg/kg以限制寄生虫传播。

临床怎么用

  • 作者认为青蒿甲醚-苯芴醇联合阿莫地喹可作为大湄公河次区域耐多药恶性疟一线治疗中青蒿甲醚-苯芴醇单药的替代方案,并可能延长青蒿甲醚-苯芴醇的治疗寿命。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Late treatment failures after artemisinin-based combination therapies (ACTs) for falciparum malaria have increased in the Greater Mekong subregion in southeast Asia. Addition of amodiaquine to artemether-lumefantrine could provide an efficacious treatment for multidrug-resistant infections. METHODS: We conducted an open-label, randomised trial at five hospitals or health centres in three locations (western Cambodia, eastern Cambodia, and Vietnam). Eligible participants were male and female patients aged 2-65 years with uncomplicated Plasmodium falciparum malaria. Patients were randomly allocated (1:1 in blocks of eight to 12) to either artemether-lumefantrine alone (dosed according to WHO guidelines) or artemether-lumefantrine plus amodiaquine (10 mg base per kg/day), both given orally as six doses over 3 days. All received a single dose of primaquine (0·25 mg/kg) 24 h after the start of study treatment to limit transmission of the parasite. Parasites were genotyped, identifying artemisinin resistance. The primary outcome was Kaplan-Meier 42-day PCR-corrected efficacy against recrudescence of the original parasite, assessed by intent-to-treat. Safety was a secondary outcome. This completed trial is registered at ClinicalTrials.gov (NCT03355664). FINDINGS: Between March 18, 2018, and Jan 30, 2020, 310 patients received randomly allocated treatment; 154 received artemether-lumefantrine alone and 156 received artemether-lumefantrine plus amodiaquine. Parasites from 305 of these patients were genotyped. 42-day PCR-corrected treatment efficacy was noted in 151 (97%, 95% CI 92-99) of 156 patients with artemether-lumefantrine plus amodiaquine versus 146 (95%, 89-97) of 154 patients with artemether-lumefantrine alone; hazard ratio (HR) for recrudescence 0·6 (95% CI 0·2-1·9, p=0·38). Of the 13 recrudescences, 12 were in 174 (57%) of 305 infections with pfkelch13 mutations indicating artemisinin resistance, for which 42-day efficacy was noted in 89 (96%) of 93 infections with artemether-lumefantrine plus amodiaquine versus 73 (90%) of 81 infections with artemether-lumefantrine alone; HR for recrudescence 0·44 (95% CI 0·14-1·40, p=0·17). Artemether-lumefantrine plus amodiaquine was generally well tolerated, but the number of mild (grade 1-2) adverse events, mainly gastrointestinal, was greater in this group compared with artemether-lumefantrine alone (vomiting, 12 [8%] with artemether-lumefantrine plus amodiaquine vs three [2%] with artemether-lumefantrine alone, p=0·03; and nausea, 11 [7%] with artemether-lumefantrine plus amodiaquine vs three [2%] with artemether-lumefantrine alone, p=0·05). Early vomiting within 1 h of treatment, requiring retreatment, occurred in no patients of 154 with artemether-lumefantrine alone versus five (3%) of 156 with artemether-lumefantrine plus amodiaquine, p=0·06. Bradycardia (≤54 beats/min) of any grade was noted in 59 (38%) of 154 patients with artemether-lumefantrine alone and 95 (61%) of 156 with artemether-lumefantrine plus amodiaquine, p=0·0001. INTERPRETATION: Artemether-lumefantrine plus amodiaquine provides an alternative to artemether-lumefantrine alone as first-line treatment for multidrug-resistant P falciparum malaria in the Greater Mekong subregion, and could prolong the therapeutic lifetime of artemether-lumefantrine in malaria-endemic populations. FUNDING: Bill & Melinda Gates Foundation, Wellcome Trust.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Peto TJ, Tripura R, Callery JJ, et al. Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial. Lancet Infect Dis. 2022. PMID: 35276064. doi:10.1016/S1473-3099(21)00692-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。